Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DIPHENHYDRAMINE ANTITUSSIVE/ANTIHISTAMINE MONOGRAPH DIRECTIONS FOR USE

This article was originally published in The Tan Sheet

Executive Summary

DIPHENHYDRAMINE ANTITUSSIVE/ANTIHISTAMINE MONOGRAPH DIRECTIONS FOR USE are among the issues that "need to be resolved before diphenhydramine can be used to perform both functions (antitussive and antihistamine)," FDA said in a notice published in the June 3 Federal Register. The agency is concerned, specifically, with the "amount of drug to be taken and time interval for taking the drug." The notice, a final rule amending the final monograph for OTC antitussives, allows the use of diphenhydramine citrate and diphenhydramine hydrochloride in single-ingredient antitussive products only.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS082866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel